|Bid||12.39 x 1200|
|Ask||12.40 x 1200|
|Day's range||11.71 - 12.65|
|52-week range||6.25 - 13.76|
|Beta (5Y monthly)||1.50|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||27 Nov 2017|
|1y target est||11.82|
Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd.(NYSE and TASE: TEVA), today announced the availability of a generic version of NuvaRing®1 (etonogestrel and ethinyl estradiol vaginal ring), 0.120 mg/0.015 mg per day, in the U.S. Teva’s AB-rated and bioequivalent etonogestrel and ethinyl estradiol vaginal ring, is an estrogen/progestin combination hormonal contraceptive (CHC) indicated for use by women to prevent pregnancy.
Since the end of the Great Recession, growth stocks have been unstoppable. Value stocks are especially strong performers during the early stages of an economic recovery, which is where we find ourselves now. As we steam ahead into the new year, the following five value stocks stand out as bargains that have the potential to make you a lot richer in 2021.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2020 financial results, as well as on its financial guidance for 2021, on Wednesday, February 10, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.